Analyst Ratings For Dova Pharmaceuticals Inc (NASDAQ:DOVA)
Today, Raymond James initiated coverage on Dova Pharmaceuticals Inc (NASDAQ:DOVA) with a Outperform.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Dova Pharmaceuticals Inc (NASDAQ:DOVA) is Buy with a consensus target price of $33.6667 per share, a potential 37.02% upside.
Some recent analyst ratings include
- 8/29/2018-Dova Pharmaceuticals Inc (NASDAQ:DOVA) has coverage initiated with a Outperform rating
- 7/15/2018-Dova Pharmaceuticals Inc (NASDAQ:DOVA) had its Buy rating reiterated by Jefferies Financial Group with a $40.00 price target
- 7/9/2018-Dova Pharmaceuticals Inc (NASDAQ:DOVA) gets downgraded to Market Perform by Leerink Swann
- 4/26/2018-Dova Pharmaceuticals Inc (NASDAQ:DOVA) has coverage initiated with a Buy rating
- 3/23/2018-Dova Pharmaceuticals Inc (NASDAQ:DOVA) has coverage initiated with a In ➝ line rating and $29.00 price target
- 7/24/2017-Dova Pharmaceuticals Inc (NASDAQ:DOVA) has coverage initiated with a Overweight ➝ Overweight rating and $35.00 price target
Recent Insider Trading Activity For Dova Pharmaceuticals Inc (NASDAQ:DOVA)
Dova Pharmaceuticals Inc (NASDAQ:DOVA) has insider ownership of 55.50% and institutional ownership of 36.53%.
- On 8/14/2018 Alex Sapir, CEO, bought 21,700 with an average share price of $22.83 per share and the total transaction amounting to $495,411.00.
- On 6/21/2018 Steven M Goldman, Director, bought 5,000 with an average share price of $30.22 per share and the total transaction amounting to $151,100.00.
- On 6/11/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 19,700 with an average share price of $29.36 per share and the total transaction amounting to $578,392.00.
- On 6/8/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 25,000 with an average share price of $28.65 per share and the total transaction amounting to $716,250.00.
- On 6/7/2018 Paul B Manning, Director, bought 27,000 with an average share price of $28.42 per share and the total transaction amounting to $767,340.00.
- On 6/6/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 100,000 with an average share price of $28.66 per share and the total transaction amounting to $2,866,000.00.
- On 6/5/2018 Paul B Manning, Director, bought 120,000 with an average share price of $26.17 per share and the total transaction amounting to $3,140,400.00.
About Dova Pharmaceuticals Inc (NASDAQ:DOVA)
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Recent Trading Activity for Dova Pharmaceuticals Inc (NASDAQ:DOVA)
Shares of Dova Pharmaceuticals Inc closed the previous trading session at 24.57 −0.85 3.34% with shares trading hands.